PHC Holdings (6523) · InitiativeAdvanced
Strategic Partnership with Cyfuse on a Regenerative Medicine Production Framework
First written in FY2024. 1 of 2 entries say "Advanced", first in FY2025. Latest entry: FY2025.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Building a Joint Development and Manufacturing and Sales ConsortiumA theme 3 companies write about · 0 as a headwind · 4 as a tailwind
2 other companies' latest entry also says "Advanced".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2025AdvancedAnnual report
「In addition, based on joint research with Cyfuse Biomedical K.K., with which the company has had a business partnership in the regenerative and cellular medicine field since 2023, the company developed new production technology using the sensor technology to improve the quality and enable stable manufacturing of 3D cell products.」
The partnership with Cyfuse Biomedical K.K. progressed beyond the basic agreement to the development, based on joint research, of technology to improve the quality and enable stable manufacturing of 3D cell products. - FY2024First statedAnnual report
「The company entered into a basic agreement on a business partnership with Cyfuse Biomedical K.K. to strengthen the strategic partnership.」
Using PHC's traceability system, the company aims to establish a production framework for the commercialization of Cyfuse Biomedical K.K.'s regenerative medicine products and other products, conduct research and technological development, and create new products.